Leucid Bio
PrivateLast Round
Series A
Extension
Feb 1, 2025
Total Funding Raised
$25.35M
Company Overview
Leucid Bio operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A Extension round in February 2025.
Leucid Bio is a biotechnology company that develops next-generation Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Leucid Bio Comparables
Compare Leucid Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inceptor Bio | 88% | |
| Innovative Cellular Therapeutics | 86% | |
| AffyImmune Therapeutics | 84% |
For institutional investors. Book with your work email.
Leucid Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Feb 1, 2025 | ||||
| Series A | Oct 21, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Leucid Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series A Extension, Series A |
| 2invest AG | Series A, Series A Extension |
| Vulpes Investment Management | Series A |
| Sofinnova Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 1, 2025
$9.5M round led by 2invest AG and Epidarex Capital
- Oct 21, 2021
$16M round led by Epidarex Capital and Vulpes Investment Management.
For institutional investors. Book with your work email.
Leucid Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Leucid Bio's valuation, stock price, and market status.
Is Leucid Bio a public or private company?
Leucid Bio is a private company.
What is the current stock price of Leucid Bio?
Leucid Bio is a private company, so its shares have no public market price. Caplight tracks Leucid Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Leucid Bio worth (valuation)?
Valuation information for Leucid Bio is not publicly available.
Can I buy Leucid Bio stock?
Leucid Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Leucid Bio's last funding round?
Leucid Bio's most recent funding round was Series A Extension on February 1, 2025.
Who are the main investors in Leucid Bio?
Key investors in Leucid Bio include Epidarex Capital, 2invest AG, Vulpes Investment Management.
Will Leucid Bio IPO soon?
No public IPO plans have been announced for Leucid Bio.
How can I track Leucid Bio secondary market activity?
Caplight tracks bids, offers, and trades in Leucid Bio's shares on secondary markets.